Table 6.
Comparison of mutant genes of ENKTL in our study and reported in the literatures.
| Study | This study | Kucuk, et.al. [12] | Lee, et.al. [13] | Jiang, et.al. [14] |
Dobashi, et.al. [15] |
|---|---|---|---|---|---|
| Year/Country | 2017/China | 2015/America | 2015/South Korea | 2015/China | 2016/Japan |
| Total Sample | 123 | 51 | 34 | 105 (3 Extra-nasal- ENKTL) |
25 (1 Extra-nasal- ENKTL) |
| Whole exon sequencing | 0 | 1 | 9 | 25 | 0 |
| Targeted sequencing | 123 | 0 | 21 | 80 | 25 |
| RNA sequencing | 0 | 30 | 0 | 0 | 0 |
| Sanger sequencing | 0 | 30 | 0 | 0 | 0 |
| STAT3 | 26.8% | 5.9% (3/51) | 26.4% | 10.4% | 8% |
| KMT2D | 18.7% | 5% (1/20) | 17.6% | 6.7% | 8% |
| DDX3X | 20.3% | 5.9% (1/17) | - | 20% | 12% |
| TP53 | 8.9% | 23.8% (5/21) | 11.8% | 13.3% | 16% |
| TET2 | 12.2% | 5.9% (1/17) | 0 | 0 | 8% |
| EP300 | 11.4% | 15% (3/20) | - | 3.8% | 0 |
| BCOR | 10.6% | 17.6% (3/17) | 20.6% | 0 | 32% |
| NOTCH1 | 9.8% | 5.9% (1/17) | - | 0 | 8% |
| CIITA | 9.8% | 11.8% (2/17) | 0 | 2.9% | 0 |
- Not tested